Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Forazapadin - Satellos Bioscience

Next Previous
Drug Profile

Forazapadin - Satellos Bioscience

Alternative Names: SAT-3247

Latest Information Update: 21 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Satellos Bioscience
  • Class Alcohols; Aldehydes; Amides; Carbamates; Carboxylic acids; Cyclopropanes; Esters; Ethers; Heterocyclic bicyclo compounds; Lactams; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Adaptor-associated kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy
  • Preclinical Facioscapulohumeral muscular dystrophy; Muscle injury

Most Recent Events

  • 14 Aug 2026 Satellos Bioscience announces intention to submit Investigational New Drug application to the US FDA for Facioscapulohumeral muscular dystrophy in the second half of 2026
  • 14 Aug 2026 Satellos Bioscience plans a phase II trial for Facioscapulohumeral muscular dystrophy in the second half of 2026
  • 08 Jul 2026 Adverse events, efficacy and pharmacodynamics data from the phase-II TRAILHEAD trial in Duchenne muscular dystrophy released by Satellos Bioscience

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top